<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1176">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04334044</url>
  </required_header>
  <id_info>
    <org_study_id>HAL 345/2020</org_study_id>
    <nct_id>NCT04334044</nct_id>
  </id_info>
  <brief_title>Treatment of SARS Caused by COVID-19 With Ruxolitinib</brief_title>
  <official_title>Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19 With Ruxolitinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Cooperativo de Hemopatías Malignas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Cooperativo de Hemopatías Malignas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In December 2019, a new virus emerged in Wuhan, China rapidly becoming a pandemic with
      registered cases above 800,000 around the world. The virus is now known as SARS-CoV2 calling
      its disease coronavirus-19 or COVID-19. The mortality of the virus has been reported around
      2-10% and its causes because of the proinflammatory immune response generated on the host.
      The cytokines involved in the immune response to COVID-19 are IL-1, IL-2, IL4, IL-6, IL-10,
      IL-12, IL-13, IL-17, GCSF, MCSF, IP-10, MCP-1, MIP-1α, HGF, IFN-γ y TNF-α.

      Ruxolitinib is an inhibitor of JAK 1/2 which is responsable for multiple cellular signals
      including the proinflammatory IL-6. Ruxolitinib works as and immunomodulator decreasing the
      cytotoxic T lymphocytes and increasing the Treg cells.

      This study is intended to stop the disregulated immune response caused by COVID-19 that
      generates the pneumonia and subsequent severe acute respiratory syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Use of ruxolitinib on patients with respiratory distress and pneumonia changes on chest computed tomography</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery of Pneumonia</measure>
    <time_frame>14 days</time_frame>
    <description>Presence of recovery of pneumonia characterized by cease of respiratory symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response of C-reactive protein</measure>
    <time_frame>14 days</time_frame>
    <description>Increment or decrease in mg/ml of C-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response of Ferritin</measure>
    <time_frame>14 days</time_frame>
    <description>Increment or decrease in ng/ml of ferritin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response of D-dimer</measure>
    <time_frame>14 days</time_frame>
    <description>Increment or decrease in mg/ml of D-dimer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ICU admission</measure>
    <time_frame>14 days</time_frame>
    <description>Requirement of Intensive Care Unit on the patients under treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of mechanical ventilation</measure>
    <time_frame>14 days</time_frame>
    <description>Requirement of mechanical ventilation on the patients under treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 month</time_frame>
    <description>Time since the diagnosis to the last follow up (recovery or death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity Rate</measure>
    <time_frame>1 month</time_frame>
    <description>Rate of adverse events associated with ruxolitinib</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>COVID-19</condition>
  <condition>Severe Acute Respiratory Syndrome Coronavirus 2</condition>
  <arm_group>
    <arm_group_label>Ruxolitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ruxolitinib 5 mg BID since the beginning of dyspnea or increment of work of breathing with pneumonia changes in chest CT-scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib Oral Tablet</intervention_name>
    <description>Ruxolitinib 5 mg twice a day</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with diagnosed COVID-19 with confirmatory test

          -  Increase in work of breathing or presence of dyspnea

          -  Presence of lung changes associated with COVID pneumonia by chest imaging

          -  Informed consent

        Exclusion Criteria:

          -  Pregnancy or breastfeeding

          -  Thrombocytopenia below 20,000 cells/mm3

          -  Neutropenia below 500 cels/mm3

          -  Known and active infection of HIV, Hepatitis C, Hepatitis B, Herpes Zoster or
             Mycobacterium Tuberculosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Grupo Cooperativo de Hemopatías Malignas</name>
      <address>
        <city>Huixquilucan</city>
        <state>Estado De México</state>
        <zip>52763</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Ovilla-Martinez, MD</last_name>
      <phone>(55)5246-5000</phone>
      <phone_ext>4830</phone_ext>
      <email>ovillarob@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Pamela E Baez Islas, MD</last_name>
      <phone>(55)5246-5000</phone>
      <phone_ext>4830</phone_ext>
      <email>drabaez.hematologia@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

